Australian miRNA developer MiReven has partnered with Silence Therapeutics to assess the delivery potential of the UK company’s lipid-based delivery systems with its novel microRNA (miRNA)-based therapeutics. The deal is the fourth such collaboration that Silence has formed in the miRNA field and will help fund the development of its internal pipeline of RNAi drug candidates. Functional delivery to target cells remains a critical challenge in the development of nucleic acid therapeutics.